Mitochondrial oxidative phosphorylation disorder

Mitochondrial oxidative phosphorylation (OXPHOS) disorders are a clinically and genetically heterogeneous group of rare metabolic diseases caused by defects in the mitochondrial respiratory chain, which is responsible for generating the majority of cellular energy in the form of ATP. The oxidative phosphorylation system comprises five enzyme complexes (Complexes I–V) embedded in the inner mitochondrial membrane, and defects can arise from mutations in either nuclear DNA or mitochondrial DNA (mtDNA) genes encoding subunits, assembly factors, or other proteins essential for respiratory chain function. Because mitochondria are present in virtually all cells, these disorders can affect any organ system, though tissues with high energy demands — such as the brain, skeletal muscle, heart, liver, kidneys, and sensory organs — are most commonly and severely impacted. Clinical manifestations are extremely variable and can present at any age, ranging from severe neonatal lactic acidosis and multisystem organ failure to milder adult-onset myopathy or progressive external ophthalmoplegia. Common symptoms include muscle weakness (myopathy), exercise intolerance, neurological problems (seizures, developmental regression, ataxia, stroke-like episodes), cardiomyopathy, hepatic dysfunction, sensorineural hearing loss, optic atrophy, and growth failure. Elevated blood or cerebrospinal fluid lactate is a frequent biochemical hallmark. Well-recognized clinical syndromes falling under this umbrella include Leigh syndrome, MELAS, MERRF, Kearns-Sayre syndrome, and Pearson syndrome, among many others. Currently, there is no curative treatment for mitochondrial OXPHOS disorders. Management is largely supportive and symptomatic, including nutritional optimization, physical therapy, management of seizures and cardiac complications, and avoidance of metabolic stressors such as fasting, illness, and certain medications (e.g., valproic acid). Cofactor supplementation with coenzyme Q10, riboflavin, thiamine, and L-carnitine is commonly employed, though evidence for efficacy remains limited. Research into gene therapy, mitochondrial replacement therapy, and novel pharmacological agents is ongoing and represents a promising frontier for these devastating conditions.

Common questions about Mitochondrial oxidative phosphorylation disorder